Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Russia has chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for primary immunization of all infants. The IPV doses are provided by M.P. Chumakov Institute of Poliomyelitis and Virus Encephalitides through a manufacturing agreement with Sanofi Pasteur.
Pfizer Launches Global Regenerative Medicine Research Unit
- Details
- Category: Pfizer
Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific progress in understanding the biology of stem cells and the opportunity that provides, to discover and develop a new generation of regenerative medicines for major medical needs.
SEROQUEL XR and SEROQUEL Approved in Europe for New Indications
- Details
- Category: AstraZeneca
AstraZeneca has announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications in bipolar disorder. SEROQUEL XR and SEROQUEL have been approved for the treatment of major depressive episodes in bipolar disorder.
Tarceva brings new hope to patients with advanced non-small cell lung cancer
- Details
- Category: Roche
Roche has announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - , significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse.
Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
- Details
- Category: Bayer
Findings from the ATLAS ACS TIMI 46 study - a Phase II study of the novel oral anticoagulant Xarelto® (rivaroxaban) - were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008 in New Orleans by C. Michael Gibson, M.D., Director of the TIMI Data Coordinating Center, Harvard Medical School, Boston, Massachusetts, USA.
CRESTOR® is in line with other marketed statins - new data from the JUPITER study
- Details
- Category: AstraZeneca
New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) and Osiris Therapeutics (Nasdaq: OSIR) have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases.
More Pharma News ...
- GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies
- AstraZeneca PLC Third Quarter and Nine Months Results 2008
- Novartis to acquire Nektar Therapeutics pulmonary business unit
- European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia
- Roche posts sustained double-digit sales growth for the first nine months of 2008
- Genzyme Reports Strong Third-Quarter Sales and Earnings Growth
- AstraZeneca Announces European SEROQUEL XR Submission